Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 244

1.

Specific elastin degradation products are associated with poor outcome in the ECLIPSE COPD cohort.

Rønnow SR, Langholm LL, Sand JMB, Thorlacius-Ussing J, Leeming DJ, Manon-Jensen T, Tal-Singer R, Miller BE, Karsdal MA, Vestbo J.

Sci Rep. 2019 Mar 11;9(1):4064. doi: 10.1038/s41598-019-40785-2.

2.

Do sputum or circulating blood samples reflect the pulmonary transcriptomic differences of COPD patients? A multi-tissue transcriptomic network META-analysis.

Faner R, Morrow JD, Casas-Recasens S, Cloonan SM, Noell G, López-Giraldo A, Tal-Singer R, Miller BE, Silverman EK, Agustí A, Hersh CP.

Respir Res. 2019 Jan 8;20(1):5. doi: 10.1186/s12931-018-0965-y.

3.

Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD.

Lazaar AL, Miller BE, Tabberer M, Yonchuk J, Leidy N, Ambery C, Bloomer J, Watz H, Tal-Singer R.

Eur Respir J. 2018 Oct 4;52(4). pii: 1801020. doi: 10.1183/13993003.01020-2018. Print 2018 Oct. No abstract available.

PMID:
30139779
4.

Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study.

Mohan D, Forman JR, Allinder M, McEniery CM, Bolton CE, Cockcroft JR, MacNee W, Fuld J, Marchong M, Gale NS, Fisk M, Nagarajan S, Cheriyan J, Lomas DA, Calverley PMA, Miller BE, Tal-Singer R, Wilkinson IB, Polkey MI; ERICA Consortium.

Thorax. 2018 Dec;73(12):1182-1185. doi: 10.1136/thoraxjnl-2018-211556. Epub 2018 Apr 4.

PMID:
29618495
5.

Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations.

Mayhew D, Devos N, Lambert C, Brown JR, Clarke SC, Kim VL, Magid-Slav M, Miller BE, Ostridge KK, Patel R, Sathe G, Simola DF, Staples KJ, Sung R, Tal-Singer R, Tuck AC, Van Horn S, Weynants V, Williams NP, Devaster JM, Wilkinson TMA; AERIS Study Group.

Thorax. 2018 May;73(5):422-430. doi: 10.1136/thoraxjnl-2017-210408. Epub 2018 Jan 31.

6.

Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study.

Wang Z, Singh R, Miller BE, Tal-Singer R, Van Horn S, Tomsho L, Mackay A, Allinson JP, Webb AJ, Brookes AJ, George LM, Barker B, Kolsum U, Donnelly LE, Belchamber K, Barnes PJ, Singh D, Brightling CE, Donaldson GC, Wedzicha JA, Brown JR; COPDMAP.

Thorax. 2018 Apr;73(4):331-338. doi: 10.1136/thoraxjnl-2017-210741. Epub 2017 Dec 21.

7.

Biomarkers of collagen turnover are related to annual change in FEV1 in patients with chronic obstructive pulmonary disease within the ECLIPSE study.

Leeming DJ, Byrjalsen I, Sand JMB, Bihlet AR, Lange P; Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators, Thal-Singer R, Miller BE, Karsdal MA, Vestbo J.

BMC Pulm Med. 2017 Dec 4;17(1):164. doi: 10.1186/s12890-017-0505-4.

8.

Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660).

Miller BE, Mayer RJ, Goyal N, Bal J, Dallow N, Boyce M, Carpenter D, Churchill A, Heslop T, Lazaar AL.

Br J Clin Pharmacol. 2017 Dec;83(12):2813-2820. doi: 10.1111/bcp.13398. Epub 2017 Sep 20.

9.

Multiple biomarkers predict disease severity, progression and mortality in COPD.

Zemans RL, Jacobson S, Keene J, Kechris K, Miller BE, Tal-Singer R, Bowler RP.

Respir Res. 2017 Jun 13;18(1):117. doi: 10.1186/s12931-017-0597-7.

10.

Integrative Genomics of Emphysema-Associated Genes Reveals Potential Disease Biomarkers.

Obeidat M, Nie Y, Fishbane N, Li X, Bossé Y, Joubert P, Nickle DC, Hao K, Postma DS, Timens W, Sze MA, Shannon CP, Hollander Z, Ng RT, McManus B, Miller BE, Rennard S, Spira A, Hackett TL, Lam W, Lam S, Faner R, Agusti A, Hogg JC, Sin DD, Paré PD.

Am J Respir Cell Mol Biol. 2017 Oct;57(4):411-418. doi: 10.1165/rcmb.2016-0284OC.

11.

Network-based analysis reveals novel gene signatures in peripheral blood of patients with chronic obstructive pulmonary disease.

Obeidat M, Nie Y, Chen V, Shannon CP, Andiappan AK, Lee B, Rotzschke O, Castaldi PJ, Hersh CP, Fishbane N, Ng RT, McManus B, Miller BE, Rennard S, Paré PD, Sin DD.

Respir Res. 2017 Apr 24;18(1):72. doi: 10.1186/s12931-017-0558-1.

12.

Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations.

Bloomer JC, Ambery C, Miller BE, Connolly P, Garden H, Henley N, Hodnett N, Keel S, Kreindler JL, Lloyd RS, Matthews W, Yonchuk J, Lazaar AL.

Eur J Pharm Biopharm. 2017 Aug;117:224-231. doi: 10.1016/j.ejpb.2017.03.023. Epub 2017 Apr 3.

PMID:
28385615
13.

Cavity-enhanced eigenmode and angular hybrid multiplexing in holographic data storage systems.

Miller BE, Takashima Y.

Opt Express. 2016 Dec 26;24(26):29465-29476. doi: 10.1364/OE.24.029465.

PMID:
28059333
14.

High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD - results from the ECLIPSE study.

Sand JM, Leeming DJ, Byrjalsen I, Bihlet AR, Lange P, Tal-Singer R, Miller BE, Karsdal MA, Vestbo J.

Respir Res. 2016 Oct 4;17(1):125.

15.

Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease.

Huang JT, Bolton CE, Miller BE, Tal-Singer R, Rabinovich RA, Palmer CN, Thomson NC, MacNee W; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.

Eur Respir J. 2016 Oct;48(4):1215-1218. doi: 10.1183/13993003.01125-2016. Epub 2016 Sep 1. No abstract available.

16.
17.

The Effect of Different Case Definitions of Current Smoking on the Discovery of Smoking-Related Blood Gene Expression Signatures in Chronic Obstructive Pulmonary Disease.

Obeidat M, Ding X, Fishbane N, Hollander Z, Ng RT, McManus B, Tebbutt SJ, Miller BE, Rennard S, Paré PD, Sin DD.

Nicotine Tob Res. 2016 Sep;18(9):1903-9. doi: 10.1093/ntr/ntw129. Epub 2016 May 6.

18.

Cavity techniques for holographic data storage recording.

Miller BE, Takashima Y.

Opt Express. 2016 Mar 21;24(6):6300-17. doi: 10.1364/OE.24.006300.

PMID:
27136822
19.

Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD.

Rabinovich RA, Miller BE, Wrobel K, Ranjit K, Williams MC, Drost E, Edwards LD, Lomas DA, Rennard SI, Agustí A, Tal-Singer R, Vestbo J, Wouters EF, John M, van Beek EJ, Murchison JT, Bolton CE, MacNee W, Huang JT; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.

Eur Respir J. 2016 May;47(5):1365-73. doi: 10.1183/13993003.01824-2015. Epub 2016 Mar 23.

20.

Free Urinary Desmosine and Isodesmosine as COPD Biomarkers: The Relevance of Confounding Factors.

Ongay S, Sikma M, Horvatovich P, Hermans J, Miller BE, Ten Hacken NHT, Bischoff R.

Chronic Obstr Pulm Dis. 2016 Mar 1;3(2):560-569. doi: 10.15326/jcopdf.3.2.2015.0159.

21.

Lung microbiome dynamics in COPD exacerbations.

Wang Z, Bafadhel M, Haldar K, Spivak A, Mayhew D, Miller BE, Tal-Singer R, Johnston SL, Ramsheh MY, Barer MR, Brightling CE, Brown JR.

Eur Respir J. 2016 Apr;47(4):1082-92. doi: 10.1183/13993003.01406-2015. Epub 2016 Feb 25.

22.

Right Bundle Branch Block and Electromechanical Coupling of the Right Ventricle: An Echocardiographic Study.

Miller BE, Rajsheker S, López-Candales A.

Heart Views. 2015 Oct-Dec;16(4):137-43. doi: 10.4103/1995-705X.172197.

23.

Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium.

Miller BE, Tal-Singer R, Rennard SI, Furtwaengler A, Leidy N, Lowings M, Martin UJ, Martin TR, Merrill DD, Snyder J, Walsh J, Mannino DM.

Am J Respir Crit Care Med. 2016 Mar 15;193(6):607-13. doi: 10.1164/rccm.201509-1722PP. Review.

PMID:
26745765
24.

The Effect of Statins on Blood Gene Expression in COPD.

Obeidat M, Fishbane N, Nie Y, Chen V, Hollander Z, Tebbutt SJ, Bossé Y, Ng RT, Miller BE, McManus B, Rennard S, Paré PD, Sin DD.

PLoS One. 2015 Oct 13;10(10):e0140022. doi: 10.1371/journal.pone.0140022. eCollection 2015.

25.

Continuous fat-free mass decline in COPD: fact or fiction?

Rutten EP, Spruit MA, McDonald ML, Rennard S, Agusti A, Celli B, Miller BE, Crim C, Calverley PM, Hanson C, MacNee W, Franssen FM, Vanfleteren L, Wouters EF; ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) Investigators.

Eur Respir J. 2015 Nov;46(5):1496-8. doi: 10.1183/13993003.00692-2015. Epub 2015 Sep 17. No abstract available. Erratum in: Eur Respir J. 2016 Nov;48(5):1533.

26.

Low plasma CC16 levels in smokers are associated with a higher risk for chronic bronchitis.

Petersen H, Leng S, Belinsky SA, Miller BE, Tal-Singer R, Owen CA, Celli B, Tesfaigzi Y.

Eur Respir J. 2015 Nov;46(5):1501-3. doi: 10.1183/13993003.00682-2015. Epub 2015 Jul 9. No abstract available.

27.

Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung.

Yonchuk JG, Silverman EK, Bowler RP, Agustí A, Lomas DA, Miller BE, Tal-Singer R, Mayer RJ.

Am J Respir Crit Care Med. 2015 Oct 1;192(7):785-92. doi: 10.1164/rccm.201501-0137PP. Review.

PMID:
26132989
28.

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects.

Miller BE, Mistry S, Smart K, Connolly P, Carpenter DC, Cooray H, Bloomer JC, Tal-Singer R, Lazaar AL.

BMC Pharmacol Toxicol. 2015 Jun 20;16:18. doi: 10.1186/s40360-015-0017-x.

29.

NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.

Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W Jr, Gaffney DK.

Cancer. 2015 Jul 1;121(13):2156-63. doi: 10.1002/cncr.29337. Epub 2015 Apr 6.

30.

Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis.

Rennard SI, Locantore N, Delafont B, Tal-Singer R, Silverman EK, Vestbo J, Miller BE, Bakke P, Celli B, Calverley PM, Coxson H, Crim C, Edwards LD, Lomas DA, MacNee W, Wouters EF, Yates JC, Coca I, Agustí A; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints.

Ann Am Thorac Soc. 2015 Mar;12(3):303-12. doi: 10.1513/AnnalsATS.201403-125OC.

PMID:
25642832
31.

Cardiac catheterization in the early post-operative period after congenital cardiac surgery.

Nicholson GT, Kim DW, Vincent RN, Kogon BE, Miller BE, Petit CJ.

JACC Cardiovasc Interv. 2014 Dec;7(12):1437-43. doi: 10.1016/j.jcin.2014.06.022.

32.

Excessive postoperative bleeding and outcomes in neonates undergoing cardiopulmonary bypass.

Guzzetta NA, Allen NN, Wilson EC, Foster GS, Ehrlich AC, Miller BE.

Anesth Analg. 2015 Feb;120(2):405-10. doi: 10.1213/ANE.0000000000000531.

PMID:
25390280
33.

A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease.

Menche J, Sharma A, Cho MH, Mayer RJ, Rennard SI, Celli B, Miller BE, Locantore N, Tal-Singer R, Ghosh S, Larminie C, Bradley G, Riley JH, Agusti A, Silverman EK, Barabási AL.

BMC Syst Biol. 2014;8 Suppl 2:S8. doi: 10.1186/1752-0509-8-S2-S8. Epub 2014 Mar 13.

34.

An aberrant leukotriene A4 hydrolase-proline-glycine-proline pathway in the pathogenesis of chronic obstructive pulmonary disease.

Wells JM, O'Reilly PJ, Szul T, Sullivan DI, Handley G, Garrett C, McNicholas CM, Roda MA, Miller BE, Tal-Singer R, Gaggar A, Rennard SI, Jackson PL, Blalock JE.

Am J Respir Crit Care Med. 2014 Jul 1;190(1):51-61. doi: 10.1164/rccm.201401-0145OC.

35.

Evaluating the role of inflammation in chronic airways disease: the ERICA study.

Mohan D, Gale NS, McEniery CM, Bolton CE, Cockcroft JR, MacNee W, Fuld J, Lomas DA, Calverley PM, Shale DJ, Miller BE, Wilkinson IB, Tal-Singer R, Polkey MI; ERICA Consortium.

COPD. 2014 Sep;11(5):552-9. doi: 10.3109/15412555.2014.898031. Epub 2014 May 15.

PMID:
24832197
36.

Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease.

McDonald ML, Cho MH, Sørheim IC, Lutz SM, Castaldi PJ, Lomas DA, Coxson HO, Edwards LD, MacNee W, Vestbo J, Yates JC, Agusti A, Calverley PM, Celli B, Crim C, Rennard SI, Wouters EF, Bakke P, Tal-Singer R, Miller BE, Gulsvik A, Casaburi R, Wells JM, Regan EA, Make BJ, Hokanson JE, Lange C, Crapo JD, Beaty TH, Silverman EK, Hersh CP; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints and COPDGene Investigators.

Am J Respir Cell Mol Biol. 2014 Nov;51(5):678-87. doi: 10.1165/rcmb.2014-0135OC.

37.

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers.

Miller BE, Smart K, Mistry S, Ambery CL, Bloomer JC, Connolly P, Sanderson D, Shreeves T, Smith R, Lazaar AL.

Eur J Drug Metab Pharmacokinet. 2014 Sep;39(3):173-81. doi: 10.1007/s13318-014-0179-8. Epub 2014 Feb 7.

38.

Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality.

Williams MC, Murchison JT, Edwards LD, Agustí A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Vestbo J, Wouters E, Yates JC, van Beek EJ, Newby DE, MacNee W; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators.

Thorax. 2014 Aug;69(8):718-23. doi: 10.1136/thoraxjnl-2012-203151. Epub 2014 Jan 28.

PMID:
24473329
39.

The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study.

Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Crim C, Duvoix A, Fauerbach PN, Lomas DA, Macnee W, Mayer RJ, Miller BE, Müller NL, Rennard SI, Silverman EK, Tal-Singer R, Wouters EF, Vestbo J; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.

Lancet Respir Med. 2013 Apr;1(2):129-36. doi: 10.1016/S2213-2600(13)70006-7. Epub 2013 Feb 1.

PMID:
24429093
40.

Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study.

O'Neal WK, Anderson W, Basta PV, Carretta EE, Doerschuk CM, Barr RG, Bleecker ER, Christenson SA, Curtis JL, Han MK, Hansel NN, Kanner RE, Kleerup EC, Martinez FJ, Miller BE, Peters SP, Rennard SI, Scholand MB, Tal-Singer R, Woodruff PG, Couper DJ, Davis SM; SPIROMICS Investigators.

J Transl Med. 2014 Jan 8;12:9. doi: 10.1186/1479-5876-12-9.

41.

Lessons from ECLIPSE: a review of COPD biomarkers.

Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, Bakke P, Calverley PM, Coxson H, Crim C, Edwards LD, Locantore N, Lomas DA, Miller BE, Rennard SI, Wouters EF, Yates JC, Silverman EK, Agusti A; ECLIPSE Study Investigators.

Thorax. 2014 Jul;69(7):666-72. doi: 10.1136/thoraxjnl-2013-204778. Epub 2013 Dec 5. Review.

PMID:
24310110
42.

Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes?

Rutten EP, Calverley PM, Casaburi R, Agusti A, Bakke P, Celli B, Coxson HO, Crim C, Lomas DA, Macnee W, Miller BE, Rennard SI, Scanlon PD, Silverman EK, Tal-Singer R, Vestbo J, Watkins ML, Wouters EF.

Ann Nutr Metab. 2013;63(3):239-47. doi: 10.1159/000353211. Epub 2013 Nov 7.

PMID:
24216978
43.

Post-DSAEK optical changes: a comprehensive prospective analysis on the role of ocular wavefront aberrations, haze, and corneal thickness.

Hindman HB, Huxlin KR, Pantanelli SM, Callan CL, Sabesan R, Ching SS, Miller BE, Martin T, Yoon G.

Cornea. 2013 Dec;32(12):1567-77. doi: 10.1097/ICO.0b013e3182a9b182.

44.

No TWEAK for COPD.

Lazaar AL, Miller BE, Francombe G, Duvoix A, Natanek SA, Polkey MI.

Eur Respir J. 2013 Oct;42(4):1142-4. doi: 10.1183/09031936.00035413. No abstract available.

45.

Trans-ethnic fine mapping identifies a novel independent locus at the 3' end of CDKAL1 and novel variants of several susceptibility loci for type 2 diabetes in a Han Chinese population.

Kuo JZ, Sheu WH, Assimes TL, Hung YJ, Absher D, Chiu YF, Mak J, Wang JS, Kwon S, Hsu CC, Goodarzi MO, Lee IT, Knowles JW, Miller BE, Lee WJ, Juang JM, Wang TD, Guo X, Taylor KD, Chuang LM, Hsiung CA, Quertermous T, Rotter JI, Chen YD.

Diabetologia. 2013 Dec;56(12):2619-28. doi: 10.1007/s00125-013-3047-1. Epub 2013 Sep 8.

46.

Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease.

Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, Reynaert N, Tal-Singer R, Wouters EF, Agustí A, Fabbri LM, Rames A, Visvanathan S, Rennard SI, Jones P, Parmar H, MacNee W, Wolff G, Silverman EK, Mayer RJ, Pillai SG; TESRA and ECLIPSE Investigators.

Am J Respir Crit Care Med. 2013 Oct 15;188(8):948-57. doi: 10.1164/rccm.201302-0247OC.

PMID:
23947473
47.

Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort.

Miller J, Edwards LD, Agustí A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Vestbo J, Wouters E, Yates JC, Macnee W; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.

Respir Med. 2013 Sep;107(9):1376-84. doi: 10.1016/j.rmed.2013.05.001. Epub 2013 Jun 19.

48.

Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort.

Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Müllerova H, Lomas DA, Wouters E, Bakke P, Rennard S, Crim C, Miller BE, Coxson HO, Yates JC, Tal-Singer R, Vestbo J; ECLIPSE Investigators.

Eur Respir J. 2013 Sep;42(3):636-46. doi: 10.1183/09031936.00195212. Epub 2013 Jun 13.

49.

In-hospital shunt occlusion in infants undergoing a modified blalock-taussig shunt.

Guzzetta NA, Foster GS, Mruthinti N, Kilgore PD, Miller BE, Kanter KR.

Ann Thorac Surg. 2013 Jul;96(1):176-82. doi: 10.1016/j.athoracsur.2013.03.026. Epub 2013 May 11.

PMID:
23673075
50.

Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.

Klopp AH, Moughan J, Portelance L, Miller BE, Salehpour MR, Hildebrandt E, Nuanjing J, D'Souza D, Souhami L, Small W Jr, Gaur R, Jhingran A.

Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):83-90. doi: 10.1016/j.ijrobp.2013.01.017.

Supplemental Content

Loading ...
Support Center